CELEX: 62017CN0527
Language: en
Date: 2017-09-05 00:00:00
Title: Case C-527/17: Request for a preliminary ruling from the Bundespatentgericht (Germany) lodged on 5 September 2017 — LN

27.11.2017   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 402/11
            
         Request for a preliminary ruling from the Bundespatentgericht (Germany) lodged on 5 September 2017 — LN
   (Case C-527/17)
   (2017/C 402/13)
   Language of the case: German
   
      Referring court
   
   Bundespatentgericht
   
      Parties to the main proceedings
   
   
      Applicant: LN
   
      Defendant: Deutsches Patent- und Markenamt
   
      Question referred
   
   Must Article 2 of Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products (1) be interpreted as meaning that, for the purposes of that regulation, an authorisation under Directive 93/42/EEC (2) for a combined medical device and medicinal product within the meaning of Article 1(4) of Directive 93/42/EEC is to be treated as a valid marketing authorisation under Directive 2001/83/EC (3), where, as part of the authorisation procedure laid down in Annex I, Section 7.4, first paragraph, to Directive 93/42/EEC, the quality, safety and usefulness of the medicinal product component has been verified by the medicinal products authority of a Member State in accordance with Directive 2001/83/EC?
   
      (1)  OJ L 152, p. 1.
   
      (2)  Council Directive 93/42/EEC of 14 June 1993 concerning medical devices (OJ 1993 L 169, p. 1).
   
      (3)  Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (OJ 2001 L 311, p. 67).